The Dermatology Digest

JUNE 14, 2024

Food and Drug Administration (FDA) has cleared InnoCare Pharma’s investigational new drug application (IND) for ICP-332, a tyrosine kinase 2 (TYK2) inhibitor that’s being studied in moderate to severe atopic dermatitis (AD). Currently, no TYK2 inhibitors have obtained marketing approval for the treatment of AD.

Dermatitis 36

Dermatitis Marketing Safety Innovations 36

The Dermatology Digest

FEBRUARY 16, 2024

for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy. The safety profile of dupilumab in CSU was generally consistent with the known safety of Dupixent in its approved dermatological indications. and Novartis Pharmaceuticals).

Pharmaceutical 36

Pharmaceutical Safety Dermatitis Therapy 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 28

Eczema Dermatitis Safety Therapy 28

The Dermatology Digest

MARCH 11, 2024

In addition, results from the phase III ARCADIA clinical trials in atopic dermatitis (AD) found that nemolizumab-treated patients who responded at 16 weeks maintained skin and itch responses through to week 48, even when dosing was reduced from every four to every eight weeks. No new safety signals were observed in this trial.

Dermatitis 36

Dermatitis Safety Dermatology Eczema 36

The Dermatology Digest

AUGUST 13, 2024

Nemolizumab was granted Breakthrough Therapy Designation in December 2019 and Priority Review in February 2024 by the U.S. The phase III OLYMPIA 1 and OLYMPIA 2 clinical trials evaluated the efficacy and safety of nemolizumab administered subcutaneously every four weeks in more than 500 patients with prurigo nodularis.

Dermatitis 36

Dermatitis Safety Clinic Dermatology 36

The Dermatology Digest

DECEMBER 18, 2023

New practice parameters from the Joint Task Force for Practice Parameter) recommend the use of topical corticosteroids or topical calcineurin inhibitors in patients with uncontrolled atopic dermatitis (AD) despite moisturizer use. Suggest the usage of crisaborole 2% ointment for mild to moderate atopic dermatitis. in a news release. “It

Dermatitis 36

Dermatitis Partnerships Therapy Safety 36

Aesthetics Advisor

MARCH 10, 2024

Randomized, double-blind, controlled trials suggest that excluding certain foods, such as eggs and chicken, can significantly improve atopic dermatitis. Eczema, also known as atopic dermatitis, is a chronic inflammatory skin disease. Previously, I talked about the safety and efficacy of other, more natural treatments.

Eczema 36

Eczema Diet Dermatitis Document 36

The Dermatology Digest

JANUARY 9, 2024

The engineered bacterium has been validated in skin cell lines and its delivery has been validated in mice. “We have developed a topical therapy with a targeted approach, using what nature already has. acnes to address atopic dermatitis. We engineered a bacterium that lives in the skin and made it produce what our skin needs.

Sebum 36

Sebum Dermatitis Safety Technology 36

The Dermatology Digest

AUGUST 4, 2023

1 Explanations for the decline included poor compliance, poor reimbursement, fear of skin cancer, and the promise of newer therapies, said Dr. Richard. After at least 12 weeks of concomitant combination therapy, their facial vitiligo scores improved, and their total body vitiligo scores improved. It’s a great adjunct therapy.

Eczema 36

Eczema Private Practice Therapy Dermatitis 36

US Dermatologt Partners

JANUARY 24, 2024

Multiple sclerosis (MS) –People with MS, especially those who receive disease-modifying therapies, are significantly more likely to develop psoriasis, according to research presented at the 2021 Consortium of Multiple Sclerosis Centers. Symptoms include abdominal cramping, changes in bowel movements, and blood in the stool.

Management 36

Management Skin Health Medical Dermatology 36

The Dermatology Digest

MAY 6, 2024

The Phase 2a trial ( NCT05984784 ) evaluates the safety, pharmacokinetics, and efficacy of IMG-007 in adult patients with moderate-to-severe AD who had inadequate response to and/or intolerant of topical therapies. Key study endpoints include safety and percent change from baseline in eczema area and severity index (EASI) over time.

Safety 36

Safety Dermatitis Therapy Dermatology 36

First Derm

DECEMBER 26, 2023

Dandruff (Seborrheic Dermatitis) Dandruff, medically known as seborrheic dermatitis , is a common scalp condition marked by excessive shedding of skin cells. Skin Conditions (Eczema, Psoriasis, Contact Dermatitis) as Causes of Dry, Itchy Scalp Various skin conditions can lead to a dry, itchy scalp: a.

Management 64

Management Dermatitis Eczema Consultation 64

The Dermatology Digest

DECEMBER 19, 2023

Aldeyra Therapeutics’ investigational RASP modulator ADX-629 performed well in a Phase 2 clinical trial of patients with atopic dermatitis (AD), according to topline results. The primary endpoint of the clinical trial was safety and tolerability. No patients experienced flare requiring rescue therapy.

Dermatitis 36

Dermatitis Eczema Clinic Therapy 36

The Dermatology Digest

MARCH 5, 2024

Pharmacokinetic (PK) data showed a half-life of approximately 75 days across doses tested and pharmacodynamic (PD) data showed, deep and sustained inhibition of key atopic dermatitis (AD) biomarkers pSTAT6 and TARC for ~3 months (longest follow-up available, with inhibition still ongoing at time of the data cut).

Injections 36

Injections Safety Sustainability Clinic 36

Aesthetics Advisor

JUNE 16, 2024

As with so many skin-care trends that have come before, this one is rooted in medicine — in this case, regenerative medicine, which is centered on developing and applying therapies to help the body heal itself. But the authors also noted that “further studies are needed to assess the long-term efficacy and safety of this technique.”

Aromatherapy 36

Aromatherapy Injections Ingredients Moisturization 36

The Dermatology Digest

JANUARY 8, 2024

This study was a 16-week, Phase 2, randomized, double-blind, parallel group, placebo controlled, dose-ranging, multicenter study that evaluated the safety and efficacy of lutikizumab in 153 adult patients with moderate to severe HS who had previously failed anti-TNF therapy. Serious adverse events (SAEs) occurred in 5.3%

Medical 36

Medical Clinic Therapy Eczema 36